| Today’s Big NewsApr 30, 2024 |
|
Therapeutic RNAs offer several advantages over other therapies due to their specificity and versatility, leading researchers to make great strides towards personalized medicine. Download the QPS white paper for insights into the future of RNA Therapies. 
|
|
| By Zoey Becker While Eli Lilly's supply for Mounjaro and Zepbound is scheduled to increase during the second half of the year, demand is still expected to outpace supply through 2024 and possibly into 2025, executives said. |
|
|
|
By Nick Paul Taylor Novartis is pumping another $180 million into its radioligand plan, handing the cash to serial dealmaker PeptiDream to expand a peptide-drug conjugate collaboration. |
By Conor Hale Philips has reached a $1.1 billion agreement to settle claims from about 58,000 people stemming from its yearslong recall of home CPAP ventilators and sleep apnea machines. |
By Kevin Dunleavy A federal judge tossed lawsuits by Bristol Myers Squibb and Johnson & Johnson, which questioned the constitutionality of the U.S. government requiring drugmakers to negotiate with Medicare on drug pricing. And AstraZeneca has filed its challenge to a federal appeals court following a similar defeat. |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now. 
|
|
By Max Bayer Harmony Biosciences is spending $35 million upfront to buy Epygenix and its epilepsy meds. It's the neuroscience biotech's second deal in less than a month after it bought an orexin-2 inhibitor from Bioproject. |
By Conor Hale GE HealthCare missed its revenue goals for the first quarter after sales in China dipped 11%, compared to the boosts the company saw in the region during the same period the year prior. |
By Angus Liu Besides the diabetes and obesity duo of Mounjaro and Zepbound, the SGLT2 inhibitor Jardiance and the CDK4/6 cancer drug Verzenio were cited as the main growth drivers for Eli Lilly’s first quarter. But both meds had some bad news to report from late-stage clinical trials. |
By Helen Floersh Finally, some bloody good news: Researchers have identified new enzymes that bring science closer to developing universal donor blood. In an article in Nature Microbiology, a team of researchers from the Technical University of Denmark and Lund University detailed how they discovered gut bacteria enzymes that remove not only A and B antigens from red blood cells but also other components that have historically hampered progress toward universal donor blood. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report. |
|
|---|
|
|
|
Wednesday, May 22, 2024 | 11am ET / 8 am PT Learn GMP regulations in pharmaceutical storage at our upcoming webinar. Discover FDA requirements, including space validation, environmental controls, and risk mitigation. Explore services like aliquoting and cold chain transportation. Register now. 
|
|
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
